Abundant enhances treatment range with new skin products
Abundant Produce (ASX:ABT) has today updated the market regarding its Abundant Natural Health (ANH) brand.
ANH is expanding its Tomato Infused Lycopene skincare treatment range, as foreshadowed in announcements relating to its recent capital raising. Six new products in total will be released in January 2018. The Lycopene range will now include a lip balm and eye cream, with these products coming onto the market in time for the Chinese New Year.
ANH will release Magnesium Sports Spray and Ache Relief Gel under the Body range, as well as Salt Soothing Gel under its Skin range for scaly skin, itchiness and irritation.
“The increased capital has given us the ability to implement a substantially expanded marketing strategy and build brand awareness in Australia and China,” ANH CEO Shanan Birkin said.
“The right product, coupled with impressive packaging and backed by an excellent communications strategy, will bring consumers to ANH and drive future revenue.”
ANH is focused on ramping up customer engagement via digital marketing channels, including social media.
Marketing manager, Claire Woods commented: “Getting our product to the consumer requires an understanding of how consumers are informing themselves, and the trend is Facebook and Instagram. ANH now has over 1200 followers, compared with less than 50 only a month ago.”
At the same time, it’s worth noting that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
Tomato Infusion Lips Alive and Eyes Alive face range
ANH’s Lycopene Face range now includes Tomato Infusion Face Revive, Lips Alive and Eyes Alive. All of these use ActiveLyco (trademark pending), which is lycopene supercritical-fluid-extracted from the company’s own tomatoes, purpose-bred and grown at Sydney University’s Plant Breeding Institute.
“We’re particularly excited about the potential for the eye cream to drive ANH Face range awareness and sales,” Birkin said.
“Eye products are the largest segment of the global facial cream market. Our products reduce multiple signs of eye aging such as fine lines, wrinkles, puffiness, dryness, and uneven skin tone, and can be applied on the go, giving them an edge over regular eye care products.”
Consumer awareness and concerns around the toxicity of eye product ingredients are driving increased demand for products containing natural ingredients. ActiveLyco uses cold-pressed, low-temperature supercritical fluid extraction processes to preserve delicate botanical structures, avoiding oxidation and keeping the active ingredients ‘alive’ so that they can protect and restore ageing skin.
Cucumber Infusion Magnesium Sports Spray and Ache Relief Gel
ANH’s dual-action sports spray and gel deliver high concentrations of magnesium and cucumber extracts to affected areas, reducing the impact of pain and cramps.
Cucumber lactic acids help to draw much-needed fluid to the muscle, while the magnesium assists in the recovery of muscles experiencing soreness, fatigue and deep ache.
Cucumber Infusion Salt Soothing Gel
This cucumber and salt infused gel can be used to assist with the treatment of psoriasis. ANH executive director, Tony Crimmins, said that he has had psoriasis himself for 30 years, having spent over $300,000 in search of relief with no results — until he began using Salt Soothing Gel.
“I have always found that an ocean swim resulted in better skin for a few days,” Crimmins said.
“Now you can keep a bottle of the beach in your bathroom, combined with cucumber extracts to keep your skin moisturised.”
According to Transparency Market Research independent experts, the global market for psoriasis treatment was worth US$7.8 billion in 2015, and is expected to expand at a 5.1 percent compound annual growth rate (CAGR) during the period from 2016 to 2024, by which time it will surge to US$12.1 billion.
ANH’s new products will be available in January 2018, and the company will announce online purchase availability via its newsletter and social media.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.